Canertinib CAS 267243-28-7

Introduction：Basic information about Canertinib CAS 267243-28-7, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Canertinib Basic information

• Product Name: Canertinib
• Synonyms: CS-152;CI-1033; PD-183805; CI1033; CI 1033; PD183805; PD 183805;CI-1033 (Canertinib, PD-183805);CI-1033(Canertinib);PD-183805;CI-1033; PD-183805;Canertinib base;Canetinib
• CAS: 267243-28-7
• MF: C24H25ClFN5O3
• MW: 485.94
• EINECS: 1308068-626-2
• Product Categories: Inhibitors
• Mol File: 267243-28-7.mol

Canertinib Chemical Properties

• Melting point: 188-190°
• Boiling point: 691.0±55.0 °C(Predicted)
• density: 1.355±0.06 g/cm3(Predicted)
• storage temp.: Inert atmosphere,Store in freezer, under -20°C
• solubility: insoluble in H2O; ≥10.1 mg/mL in EtOH; ≥12.15 mg/mL in DMSO with gentle warming
• pka: 12.09±0.43(Predicted)
• form: Yellow powder.
• color: Light yellow to yellow
• CAS DataBase Reference: 267243-28-7

Canertinib Usage And Synthesis

Uses

Canertinib is a kind of irreversible pan-erbB tyrosine kinase inhibitor used to treat cancer.

Uses

CI-1033 is a potent inhibitor of EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, respectively.

Uses

Antineoplastic; irreversible pan-erbB tyrosine kinase inhibitor used to treat cancer.

Definition

ChEBI: A quinazoline compound having a 3-chloro-4-fluoroanilino group at the 4-position, a propenamido group at the 6-position, and a 3-morpholinopropoxy group at the 7-position.

Biological Activity

canertinib (also known as ci-1033), a 3-chloro, 4-fluoro, 4-anilinoquinazoline, is an orally available, potent and irreversible pan-erbb tyrosine kinase inhibitor that inhibits egfr, her2 and her4 in vitro with the half maximal inhibition concentration ic50 of 0.8 nm, 19 nm and 7 nm respectively [1].canertinib irreversibly binds into the atp pocket within the tk domain of all erbb family members, where the acrylamide side-chain at position c6 of canertinib is brought into close proximity with cysteines of erbb members, followed by the rapid formation of a covalent bond, which permanently inactivates the catalytically active erb1, erb2 and erb4 family members and effectively inhibits erbb3-dependent signaling [2].

in vivo

Canertinib shows superior in vivo antitumor activity, giving growth delays in A431 xenografts exceeding 50 days following oral administration^[1]. The growth of human malignant melanoma xenografts, RaH3 and RaH5, in nude mice is significantly inhibited by i.p. injections of 40 mg/kg/day canertinib (Fig. 4). The anti-proliferative effect on melanoma xenografts is visible already within 4 days of treatment and further increased throughout the treatment period as observed through the differences in tumor volumes, reaching statistical significance within 18 days of treatment^[2].

IC 50

EGFR: 7.4 nM (IC₅₀); ErbB2: 9 nM (IC₅₀)

references

[1] michelle arkin, mark m. moasser. her2 directed small molecule antagonists. curr opin investig drugs. author manuscript; available in pmc 2011 february 1. published in final edited form as: curr opin investig drugs. 2008 december; 9(12): 1264–1276.
[2] calvo e, tolcher aw, hammond la, patnaik a, de bono js, eiseman ia, olson sc, lenehan pf, mccreery h, lorusso p, rowinsky ek. administration of ci-1033, an irreversible pan-erbb tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase i pharmacokinetic and food effect study. clin cancer res. 2004 nov 1;10(21):7112-20.